• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Merck & Co (NY:MRK)

    129.19 +1.19 (+0.93%)
    Streaming Delayed Price Updated: 11:51 AM EDT, Aug 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Merck & Co

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    News headline image
    Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future
    As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed... 
    Via Finterra
    Topics Artificial Intelligence Earnings Economy
    Merck & Co. Inc. (NYSE:MRK) Offers a Steady Dividend Backed by Strong Fundamentals ↗
    Via Chartmill
    News headline image
    Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
    In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500... 
    Via MarketMinute
    Topics Economy Intellectual Property Stocks
    News headline image
    Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
    As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the... 
    Via Finterra
    Topics Initial Public Offering
    News headline image
    Merck Just Made a Big Bet on a New Cancer Growth Engine ↗
    Via MarketBeat
    News headline image
    Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks ↗
    The Schwab U.S. Dividend Equity ETF is increasing its allocation to healthcare dividend stocks. 
    Via The Motley Fool
    Topics ETFs Stocks
    News headline image
    Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    1 Reason Eli Lilly Stock Is Still a Buy ↗
    Eli Lilly is much more than just a weight loss stock. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    2 Healthcare Stocks That Could Soar Over the Next 5 Years ↗
    They could make important breakthroughs in their target markets. 
    Via The Motley Fool
    News headline image
    MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
    The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the... 
    Via MarketMinute
    Topics Intellectual Property
    ARM Makes Its Move While Wall Street Watches the Strait ↗
    Via Chartmill
    News headline image
    The Strategic Renaissance: Why 2026 is the Year of the Takeover Tailwind
    As of March 25, 2026, the global financial markets are witnessing a seismic shift in corporate strategy, marking the definitive end of the "deal winter" that chilled boardrooms for much of the early... 
    Via MarketMinute
    Topics Artificial Intelligence Economy
    News headline image
    The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition
    On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash... 
    Via Finterra
    Topics Initial Public Offering Intellectual Property World Trade
    News headline image
    Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience
    As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history. Known globally as a titan of oncology and vaccines, the Rahway, New Jersey-based... 
    Via Finterra
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
    From Terns Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    1 S&P 500 Stock to Target This Week and 2 We Ignore
    The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ... 
    Via StockStory
    Topics Stocks
    News headline image
    Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield
    Shares of pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) climbed 3.3% in early trading on Monday, March 23, 2026, after the company issued a surprisingly robust financial outlook for the fiscal... 
    Via MarketMinute
    Topics Economy Initial Public Offering Intellectual Property
    News headline image
    Pfizer vs Moderna: Which Pharma Stock Has More Upside? ↗
    They aren't just "pandemic stocks." 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms
    In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from... 
    Via MarketMinute
    Topics Artificial Intelligence Intellectual Property
    News headline image
    The Grand Divergence: Finance Surges as Health Care Braces for a Historic Q1 Earnings Slump
    As the first quarter of 2026 draws to a close, the S&P 500 is witnessing one of the most dramatic sector performance splits in recent financial history. According to consensus estimates as of March 17,... 
    Via MarketMinute
    Topics Earnings Economy Initial Public Offering
    News headline image
    Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
    From Merck Sharp & Dohme
    Via Business Wire
    News headline image
    The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery
    The biotech sector has found its new North Star in 2026. As of mid-March, Moderna Inc. (NASDAQ: MRNA) has shocked Wall Street with a staggering 83% year-to-date gain, catapulting it to the upper... 
    Via MarketMinute
    Topics Artificial Intelligence Initial Public Offering Stocks
    News headline image
    Merck & Co. Trades Ex-Dividend as Healthcare Emerges as a Volatility Hedge in 2026
    Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors... 
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research
    From Merck & Co., Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.